The remaining three studies without MMSE baseline or specific values suggested that DPP‐4 inhibitors can significantly improve cognitive function in patients with type 2 diabetes mellitus compared with other oral hypoglycemic agents. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.